Xcovery has started a Phase II clinical trial of ensartinib (X-396) to treat patients with advanced malignant melanoma possessing alterations in anaplastic lymphoma kinase (ALK), including ALK(ATI).

The open-label, single-arm study is enrolling patients with melanoma who currently or previously received a PD-1 based therapy, and a BRAF-based therapy if BRAF V600 is mutated.

The trial is being conducted by Memorial Sloan Kettering Cancer Center (MSK) in the US and is led by MSK department of medicine/melanoma and immunotherapeutics services representative Dr Alexander Shoushtari. It includes the screening and treatment phases.

During the screening phase, archival tumour tissues from current and future patient candidates for this trial will be tested for ALK(ATI) alteration using a Nanostring-based RNA assay at MSK.

Patients whose tumours express ALK(ATI) will be eligible to take part in the trial’s treatment phase.

The trial’s primary endpoint is to determine the clinical benefit rate (CBR) of ensartinib in this patient population.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“This trial could represent a new treatment option for patients who currently have few options.”

CBR will be defined by response evaluation in solid tumours (RECIST) 1.1 or stable disease until the 24-week assessment.

Shoushtari said: “While there has been significant clinical advancements in the treatment of advanced malignant melanoma, 30% to 40% of patients do not respond to immune-based therapy or will develop therapeutic resistance.

“This is a promising trial that uses an RNA-based assay to identify an epigenentically regulated tumour growth mechanism and if deemed favourable for further study, this trial could represent a new treatment option for patients who currently have few options.”

The ensartinib (X-396) is a potent ALK inhibitor currently being studied in a global Phase lll trial in ALK positive non-small cell lung cancer patients.

Alongside ALK, ensartinib potently inhibits TRKA fusions, TRKC, ROS1, EphA2, and c-MET.